A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia-Reference-Cited by-同舟云学术

A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia

Published:2014-06-19 Issue:25 Volume:123 Page:3887-3894
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Bussel James B.¹,Kuter David J.²,Aledort Louis M.³,Kessler Craig M.⁴,Cuker Adam⁵,Pendergrass Kelly B.⁶,Tang Shande⁷,McIntosh Joe⁷

Affiliation:

1. Division of Hematology, Departments of Pediatrics and Medicine, Weill Medical College of Cornell University, New York, NY;

2. Hematology Department, Massachusetts General Hospital, Boston, MA;

3. Division of Hematology/Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY;

4. Division of Coagulation, Georgetown University Medical Center, Washington, DC;

5. Department of Medicine and Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA;

6. Kansas City Cancer Center, Kansas City, MO; and

7. Eisai Corporation of North America, Woodcliff Lake, NJ

Abstract

Key Points Once-daily oral avatrombopag dose-dependently raised PCs over 28 days, with stable counts maintained over a 24-week extension. Low rates of severe AEs and study drug discontinuations due to AEs occurred despite dose increases in maintenance.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/25/3887/1464368/3887.pdf

Reference20 articles.

1. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP.;McMillan;Blood,2004

2. Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study.;Nørgaard;Blood,2011

3. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production.;Nugent;Br J Haematol,2009

4. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.;Rodeghiero;Blood,2009

5. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts.;Cohen;Arch Intern Med,2000

Cited by 118 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thrombopoietin Receptor Agonists in Post-Hematopoietic Cell Transplantation Complicated by Prolonged Thrombocytopenia: A Comprehensive Review;ImmunoTargets and Therapy;2024-09

2. Immune thrombocytopenia (ITP): historical perspectives, pathophysiology, and treatment advances;Discover Medicine;2024-07-02

3. Update on the Use of Thrombopoietin-Receptor Agonists in Pediatrics;Hämostaseologie;2024-06-26

4. Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial;Annals of Hematology;2024-06-06

5. Data mining and safety analysis of avatrombopag: a retrospective pharmacovigilance study based on the US food and drug administration’s adverse event reporting system;Scientific Reports;2024-05-17